个性化文献订阅>期刊> Journal of Medicinal Chemistry
 

Discovery of a Potent, Selective, and Orally Bioavailable c-Met Inhibitor: 1-(2-Hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2- yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458).

  作者 Liu, Longbin;Siegmund, Aaron;Xi, Ning;Kaplan-Lefko, Paula;Rex, Karen;Chen, April;Lin, Jasmine;Moriguchi, Jodi;Berry, Loren;Huang, Liyue;Teffera, Yohannes;Yang, Yajing;Zhang, Yihong;Bellon, Steven F.;Lee, Matthew;Shimanovich, Roman;Bak, Annette;Dominguez,  
  选自 期刊  Journal of Medicinal Chemistry;  卷期  2008年51-13;  页码  3688-3691  
  关联知识点  
 

[摘要]Deregulation of the receptor tyrosine kinase c-Met has been implicated in human cancers. Pyrazolones with N-1 bearing a pendent hydroxyalkyl side chain showed selective inhibition of c-Met over VEGFR2. However, studies revealed the generation of active, nonselective metabolites. Blocking this metabolic hot spot led to the discovery of 17 (AMG 458). When dosed orally, 17 significantly inhibited tumor growth in the NIH3T3/TPR-Met and U-87 MG xenograft models with no adverse effect on body wt.

 
      被申请数(0)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内